New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:11 EDTBDSIBioDelivery Sciences and Endo Pharmaceuticals report on BEMA Buprenorphine NDA
BioDelivery Sciences International announced that along with its commercial partner, Endo Pharmaceuticals, engaged in a positive pre-New Drug Application, or NDA, meeting with the FDA regarding BEMA Buprenorphine for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate. The positive outcome of the pre-NDA meeting allows BDSI and Endo to maintain expectations of an NDA filing with FDA for BEMA Buprenorphine in late 2014 or early 2015 as planned.
News For BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
09:02 EDTBDSIAcceptance of NDA for Belbuca triggers $10M milestone payment to BDSI
Subscribe for More Information
07:31 EDTBDSIEndo, BioDelivery Sciences announce acceptance of NDA for Belbuca
Subscribe for More Information
February 20, 2015
08:21 EDTBDSISummer Street still feels Endo could acquire BioDelivery Sciences
Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use